0123-9015
0123-9015
S0123-90152020000500192
10.35509/01239015.690
Colombia
Colombia
Colombia
Colombia
Colombia
Peru
Colombia
Colombia
USA
USA
Venezuela
México
México
Paraguay
Perú
Peru
Argentina
Ecuador
Uruguay
Colombia
Bolivia
Chile
Chile
Guatemala
00
12
2020
00
12
2020
24
192
226
[
2020
172
11
11
756-8
]
[
2020
31
7
7
894-901
]
[
2020
39
1
1
11-20
]
[
2016
1863
3
3
471-82
]
[
2018
103
8
8
1256-68
]
[
2019
37
37
80-1
]
[
2020
]
[
2016
91
6
6
302-10
]
[
1996
]
[
2020
26
6
6
1257-65
]
[
2018
23
3
3
6775-7
]
[
2020
579
7798
7798
270-3
]
[
2020
26
4
4
450-2
]
[
2020
94
94
44-8
]
[
2020
368
368
m1091
]
[
2020
9
9
29
]
[
2020
35
35
101613
]
[
2020
368
368
m1198
]
[
2018
42
42
]
[
2020
21
3
3
335-7
]
[
2020
179
179
A1-2
]
[
2019
66
66
1-8
]
[
1986
4
6
6
859-65
]
[
1993
329
22
22
1608-14
]
[
1997
15
3
3
1110-7
]
[
2018
36
16
16
1603-10
]
[
2019
5
1
1
83
]
[
]
[
American Society of Hematology
2020
]
[
GELTAMO
]
[
2020
11
3
3
196
]
[
2017
12
12
10
]
[
2018
34
3
3
454-9
]
[
2015
2015
2015
550-8
]
[
2017
178
5
5
739-46
]
[
1998
34
10
10
1514-21
]
[
2008
61
5
5
785-90
]
[
2019
88
88
102925
]
[
2017
35
4
4
584-90
]
[
2001
91
8
8
1557-62
]
[
2017
176
4
4
591-9
]
[
2020
126
2
2
293-303
]
[
2004
15
10
10
1484-9
]
[
2020
143
143
40-50
]
[
2018
19
2
2
257-66
]
[
2002
49
49
S13-20
]
[
2014
32
31
31
3490-6
]
[
]
[
]
[
2016
37
1
1
829-35
]
[
2012
13
2
2
196-206
]
[
2020
]
[
2014
32
17
17
1782-91
]
[
2017
4
6
6
e272-82
]
[
]
[
2017
34
34
2210-31
]
[
European Centre for Disease Prevention and Control.
2020
]
[
Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea, (GELTAMO)
]
[
Sociedad Argentina de Hematología
]
[
2020
24
3
3
]
[
2020
12
4
4
372
]
[
The European Medicines Agency, (EMA).
2020
]
[
Centers for Disease Control and Prevention
2020
]
[
Ministerio de Salud y Protección Social, Colciencias, Instituto Nacional de Cancerología ESE
2017
]
[
2020
105949
]
[
Hospital Israelita Albert Einstein
]
[
2020
95
6
6
P1213-21
]
[
]
[
2020
1
1
]
[
2020
26
7
7
1631-3
]
[
The New York Times
2020
]
[
2020
212
10
10
481-9
]
[
World Health Organization
]
[
2019
20
1
1
592
]
[
FDA Statement
2020
]
[
]
[
AABB
2020
]
[
2020
202004168
202004168
]
[
2017
58
8
8
1814-22
]
[
2020
25
25
1-10
]
[
World health Organization
2020
1-40
]
[
2014
25
9
9
1709-18
]
[
2014
90
3
3
190-9
]
[
2005
90
90
]
[
2006
17
iv25-30
]
[
2000
18
21
21
3633-42
]
[
1988
71
1
1
117-22
]
[
2015
29
3
3
185-98
]
[
2017
25
11
11
3295-04
]
[
2019
25
7
7
1638-44
]
[
2016
30
9
9
838-46
]
[
2005
353
353
977-87
]
[
2012
1
1
]
[
2018
76
1
1
20-37
]
[
2018
36
30
30
3043-54
]
[
2004
22
22
4302-11
]
[
2000
37
351-60
]
[
2018
9
9
2264
]
[
2018
24
11
11
2293-301
]
[
2019
9
1
1
55
]
[
2020
15
1
1
62
]
[
2020
]
[
]
[
2020
107
3
3
600-1
]
[
ESTRO
]
[
2020
22
22
55-68
]
[
NICE (National institute for Health and Care excellence)
2020
]
[
2020
1-9
]
[
2020
9
9
1563
]
[
2020
61
5
5
1119-25
]
[
2019
3
6
6
]
[
2020
54
9
9
879-98
]
[
2020
11
11
]
[
2018
29
3
3
715-23
]
[
2020
29
10
10
625-6
]
[
Sociedad Española de Hematología y Hemoterapia, SEHH
2020
]
[
]
[
2020
20
5
5
553-8
]
[
2020
7
5
5
e365-6
]
[
2020
25
6
6
1-2
]
[
2020
]
[
FDA
]
[
Working Group coordinated by the, EMA
2020
]
[
2020
20
3
3
201-2
]
[
]
[
2020
189
2
2
241-3
]
[
]
[
National University Cancer Institute of Singapore (NCIS) Workflow Team
2020
31
7
7
840-3
]
[
2020
1-4
]
[
American Society of Hematology
2020
]
[
ASCO
2020
]
[
2017
36
1
1
37-43
]
[
Centers for Medicare & Medicaid Services
]
[
ATA
2019
]
[
American Medical Association
2020
]
[
National Comprehensive Cancer Network
]
[
American Society of Hematology
]
[
2020
21
4
4
]
[
2012
118
16
16
3977-83
]
[
2019
37
21
21
1790-9
]
[
2013
381
9880
9880
1817-26
]
[
2015
169
2
2
188-98
]
[
2006
106
7
7
1569-80
]
[
2013
369
20
20
1915-25
]
[
2017
130
]
[
2002
13
8
8
1264-74
]
[
2020
41
2
2
145-51
]
[
2011
12
5
5
460-8
]
[
2004
104
3
3
634-41
]
[
2019
103
5
5
460-71
]
[
2008
9
2
2
105-16
]
[
2018
131
2
2
174-81
]
[
2012
23
1
1
147-53
]
[
2017
35
2
2
151-7
]
[
2017
130
7
7
867-74
]
[
2014
111
6
6
1072-9
]
[
2015
168
5
5
654-62
]
[
2012
120
21
21
151
]
[
2020
4
5
5
858-67
]
[
2019
9
9
13544
]
[
2015
126
6
6
739-45
]
[
2016
387
10020
10020
770-8
]
[
2018
391
10121
10121
659-67
]
[
2012
13
7
7
716-23
]
[
2013
381
9873
9873
1203-10
]
[
2017
377
14
14
1331-44
]
[
2019
37
12
12
984-91
]
[
2014
124
21
21
3048
]
[
2017
35
7501
]
[
2005
105
7
7
2677-84
]
[
2014
124
15
15
2354-61
]
[
2005
104
7
7
1434-41
]
[
2007
86
2
2
101-5
]
[
2009
144
4
4
524-30
]
[
2000
1
2
2
87-94
]
[
2017
58
58
34-40
]
[
2019
37
31
31
2815-24
]
[
2018
36
22
22
2259-66
]
[
2006
17
9
9
1418-23
]
[
2016
34
34
]
[
2015
26
11
11
2323-8
]
[
2017
377
13
13
1250-60
]
[
2020
38
3
3
248-56
]
[
2005
23
30
30
7614-20
]
[
2018
29
29
iv19-29
]
[
2013
2013
2013
1-9
]
[
2020
]
[
2016
374
25
25
2419-29
]
[
2018
378
4
4
331-44
]
[
2020
12
3
3
1-15
]
[
2020
5
2
2
]
[
2019
77
77
44-56
]
[
2020
1
1
1
]
[
2017
10
1
1
85
]
[
2020
]
[
2018
131
23
23
252840
]
[
BC Cancer Agency Cancer Drug Manual©.
2013
]
[
2010
149
3
3
410-3
]
[
2020
18
5
5
1094-9
]